Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study
Authors' conclusion
LLDAS and CR were attainable treat-to-target of belimumab plus SoC therapy in cSLE.
Study context
- Population
- Patients with active childhood-onset SLE (cSLE), 15 centres in China92.2% female
- Participants
- 193 patients
- Exposure
- Belimumab plus standard of care (SoC) therapy, pre-post
- Belimumab + SoCn = 193
- Outcome
- Proportion achieving LLDAS and clinical remission (CR)
- Follow-up
- 3, 6 and 12 months
Methodological detailsmulticentre, one arm
- Multicentre
- One arm
Main finding
As reported in the abstract
LLDAS (CR)
Low lupus disease activity status (LLDAS) (clinical remission (CR)) at 3 months
12.4%
1.0%
LLDAS (CR) at 6 months
25.6%
4.5%
LLDAS (CR) at 12 months
70.3%
29.7%
Observational data: associations, not effects.
Further findings
Mean SELENA-SLEDAI score
- Baseline
- 11.0
- 3 months
- 3.7
- 6 months
- 2.9
- 12 months
- 1.7
Prednisone-equivalent steroid dose, mean (SD)
mg/day
- Baseline
- 31.0 (18.2)
- Month 3
- 19.4 (10.8)
- Month 6
- 12.6 (7.2)
- Month 12
- 6.7 (5.3)
- All patients received steroids at baseline
Symptoms and immunological indicators
- Significantly improved
Original publication
Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study. Rheumatology (Oxford). Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →